版本:
中国

BRIEF-Daiichi Sankyo announces new analyses

March 13 Daiichi Sankyo Co Ltd:

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session

* Daiichi Sankyo Co Ltd says edoxaban was found to be superior for principal safety endpoint of major bleeding in comparison to warfarin Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐